Aug 17, 2026 08:30AM
Aug 4, 2026 08:04AM
Aug 4, 2026 08:00AM
Jul 30, 2026 08:31AM
Jul 30, 2026 08:31AM
Jul 13, 2026 08:01AM
Jul 13, 2026 08:00AM CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
Jun 24, 2026 08:00AM
Jun 24, 2026 08:00AM
Jun 16, 2026 04:01PM
Jun 16, 2026 04:01PM
Jun 16, 2026 08:02AM
Jun 16, 2026 08:00AM
Jun 15, 2026 03:02AM CEL-SCI prices $2.5 million share offering at $1.00 per share
Jun 14, 2026 07:03PM
Jun 12, 2026 08:00AM
Jun 12, 2026 08:00AM
May 18, 2026 08:00AM
May 13, 2026 03:00PM
May 13, 2026 03:00PM
May 11, 2026 08:11PM CEL-SCI prices $7.2 million public offering at $1.20 per share
May 11, 2026 08:11PM
May 11, 2026 08:00AM
May 11, 2026 08:00AM
Feb 18, 2026 09:00AM
Dec 29, 2025 09:00AM
Aug 29, 2025 12:52PM
Aug 29, 2025 12:52PM CEL-SCI Announces Closing of $10 Million Public Offering
Aug 27, 2025 10:35PM
Aug 27, 2025 10:35PM
Aug 27, 2025 05:25PM
Aug 27, 2025 05:25PM
Aug 14, 2025 10:45AM
Aug 13, 2025 09:17AM
Aug 13, 2025 09:15AM CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Whic
Jul 14, 2025 04:07PM
Jul 14, 2025 04:05PM
Jul 11, 2025 12:16PM
Jul 11, 2025 12:16PM
Jul 11, 2025 09:15AM
Jul 11, 2025 09:15AM
Jun 18, 2025 09:00AM CEL-SCI Corp (CVM): FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway
Jun 18, 2025 09:00AM
May 23, 2025 04:05PM
May 22, 2025 05:44AM
May 21, 2025 08:14PM
May 21, 2025 04:13PM
May 21, 2025 04:05PM
May 21, 2025 08:08AM CEL-SCI Corp's (CVM) Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
May 21, 2025 08:00AM

328,912 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All